Development and differentiation of the mammary gland is dependent on the appropriate temporal expression of both systemically acting hormones and locally produced growth factors. A large body of evidence suggests that molecular crosstalk between these hormonal and growth factor axes are crucial for appropriate cell and tissue function. Two of the most important trophic factors involved in this process are the oestrogen (E) and insulin-like growth factor (IGF) molecular axes. The reciprocal crosstalk that exists between these pathways occurs at transcriptional/posttranscriptional and translational/post-translational levels regulates the expression and activity of genes involved in this process .In a clinical context an important consequence of such crosstalk in the mammary gland is the role which it may play in the aetiology, maintenance and development of breast tumours. Although oestradiol (E 2 ) acting through oestrogen receptors and (ER / ) is important for normal mammary gland function it can also provide a mitogenic drive to ER+ breast tumours. Therefore over several years anti-oestrogen therapeutic regimens in the form of selective oestrogen receptor modulators (SERMs -e.g. tamoxifen), aromatase inhibitors (AI e.g. anastrozole) or selective oestrogen receptor down regulators (SERDs -e.g. fulvestrant) have been used in an adjuvant setting to control tumour growth. Although initial response is usually encouraging, large cohorts of patients eventually develop resistance to these treatments leading to 2 tumour recurrence and poor prognosis .Although there are potentially many routes by which breast cancer (BC) cells could escape anti-oestrogen based therapeutic strategies one of the most studied is the putative growth factor mediated activation of ER(s). Such E-independent activation of ER could provide a route of escape from classical anti-oestrogen based therapeutic strategies. Because of this growth factor modulation of ER activity has been an intensively studied route of molecular crosstalk in the mammary gland. The insulin-like growth factors (IGF-1 and -2) are amongst the most potent mitogens for mammary epithelial cells and there is accumulating evidence that they interact with the E 2 axis to regulate mitogenesis, apoptosis, adhesion, migration and differentiation of mammary epithelial cells. Such interactions are also bi-directional and E 2 has been shown to regulate the expression and activity of IGF axis genes with the general effect of sensitising breast epithelial cells to the actions of IGFs and insulin. In this short review we discuss the evidence for the involvement of crosstalk between the insulin-like growth factor (IGF) and oestrogen axes in the mammary gland and comment on the relevance of such studies in the aetiology and treatment of BC.
Introduction
In the mammary gland IGF activity is regulated as part of a multi-component molecular axis comprising the growth factors themselves IGF-1 and IGF-2; the cell surface IGF-1 and IGF-2 receptors: IGF-IR and IGF-2R; and six well characterised soluble IGF binding proteins: IGFBP 1-6 [1, 2] . Ancillary members of the axis include IGFBP related proteins IGFBPrP-1 and 2 -sometimes called IGFBP-7 and -8 [3, 4] , specific and non-specific IGFBP proteases [5] and an acid labile subunit (ALS) protein which complexes with IGFBP-3 and IGFBP-5 in serum and interstitial fluids [6] . IGF-1 and -2 are small (~7.5kDa) polypeptides which show structural and functional homology to insulin [7] although unlike insulin IGFs are expressed by several tissues and cell types. The IGF-1R also shows a high degree of homology with the insulin receptor (IR) and hybrid IGF-1R/insulin receptor species have been reported for both the A and B isoforms of the insulin receptor ( IR-A / IR-B) comprising an IGF-1R dimer combined with an dimer of the IR-A or IR-B isoform. Although the physiological significance of hybrid receptor expression remains unknown they have been reported in BC cells [8] . The IGF-2R has no structural homology to either IGF-1R or IR and is a single chain transmembrane protein identical to the cation-independent mannose-6-phosphate receptor [9] .
This partial structural homology amongst the ligands and receptors in the IGF and insulin family leads to a degree of promiscuity in ligand binding and also results in some functional redundancy between IGF-1, IGF-2 and insulin polypeptides [10] .
Binding of IGF-I to IGF-1R leads to recruitment of adaptor proteins belonging to the insulin receptor substrate (IRS) family of proteins to autophosphorylated regions within the cytosolic domain of IGF-1R with subsequent activation of downstream signalling molecules including Shc/Grb2, Ras/Raf-1, MAPK/Erk and PI3K/Akt.
Ultimately such signalling pathways control various cellular functions including mitogenesis, apoptosis, adhesion, migration and differentiation [11] .
IGF activity is modified by soluble high affinity IGFBPs which are present ubiquitously in biological fluids. IGFBPs can exert enhancing or inhibiting effects on IGF action [12, 13] or display IGF independent effects [14, 15] . IGFBPs are secreted by several cell types and show tissue specific expression profiles. They are expressed and secreted by BC cell lines and primary breast tissue cultures and the role of these proteins in the regulation of normal and abnormal breast epithelial cell function has been intensively studied. IGFBPs are substrates for IGFBP proteases which act to release IGFs from IGFBPs allowing access of growth factors to cell surface receptors. BC cell lines and primary cultures also express and secrete such proteases [16, 17] and it is suggested that the activity of these enzymes may regulate access of growth factors to malignant breast epithelial cells [18] . 
IGF axis expression and function in mammary gland
In vitro cell culture models (mainly BC lines) have been used extensively to examine IGF axis effects on various biological end points including cell mitogenesis, migration, adhesion, apoptosis and less commonly differentiation [1, 12, 14, 15] .
Although the data generated is on occasion contradictory, in some instances findings reported in vitro have been confirmed in vivo by the use of conditional knock out or tissue specific over expression of IGF axis genes in the mammary gland.
Initially the role of IGFs in the function of normal and malignant breast tissue was the subject of some controversy. This was mainly due to reports of low or absent IGF expression in cultures of mammary epithelial cell lines or primary breast epithelial cell cultures. Although early reports described the accumulation of IGF-1 in medium conditioned by BC lines [19, 20] this activity was subsequently shown to be associated with incomplete extraction of IGFBPs from media samples leading to an over estimation of IGF activity by radio-immunoassay procedures in use at that time [21, 22] . mRNA analysis confirmed very low levels of IGF-1 and -2 expression in BC epithelial cells [23] and although experiments with an inhibitory monoclonal antibody( Mab) specific for the IGF-1R suggested an autocrine role for secreted IGF-1 in BC epithelial cell proliferation [24] such experiments were often confounded by the use of inappropriate basal culture conditions used to examine the effects of added growth factors on cell division [25] . suggested that IGFBP sequestration of growth factor inhibited IGF action in BC cells [42, 43] . Accordingly agents which increased pericellular IGFBP, including vitamin D analogues and anti-oestrogens (see below) attenuated the mitogenic activity of IGFs in BC cultures. However, a major confounding factor is the many observations which report an enhancing action of IGFBPs on IGF activity in BC cells [12] [13] [14] . Although the mechanisms of these enhancing effects are not fully elucidated amongst the theories postulated include the establishment of a low affinity "sink" formed by ECM bound IGFBP-IGF complexes (see Fig 1) or an increased half-life of IGFBP bound IGF compared with free IGF. It has also been suggested that IGFBPs may inhibit the IGF-1 induced desensitisation of IGF-1R and prolong the activity of growth factor [13] and some reports also indicate that IGFBPs may have a direct IGF independent activity in breast tissues [44] . These findings introduce a further layer of complexity to studies which examine the activity of the IGF axis in BC cell physiology and are especially important for a full understanding of potential mechanisms involved in cross talk between IGF axis and other hormones/growth factors in normal mammary gland and BCs.
In BC cells the profile of IGFBP expression is cell line specific and correlates with oestrogen receptor (ER) status. ER+ MCF-7 cells express IGFBP-2, -4 and -5 at moderate to high levels [45] [46] [47] [51, 53, [57] [58] [59] [60] .However the mechanism by which such effects occur is not fully established and regulation of IGFBP-3 concentration was often evident at the post transcriptional level and in some instances was not associated with concomitant increases in IGFBP concentrations in conditioned medium [58, 59] . Such disjunction between gene expression and protein secretion may be due to proteolysis of IGFBPs and proteases which act on binding proteins are expressed in BC cells [16, 17] . This further highlights some of the difficulties in interpretation of IGF axis effects on mammary epithelial cells and in the potential disruption of the axis which may occur in BC cells.
IGF -E crosstalk: general considerations
The observation that IGF and oestrogen axes interact within the mammary gland to regulate mammary cell physiology is well established and is an active research area. Further studies into the molecular details associated with co-regulation of mammary gland gene expression and the potential significance for BC treatment is fully warranted.
IGF axis effects on ER function
Since early studies using subcutaneous implants of des (1-3) IGF-1 (an IGF-1 analogue with reduced affinity for IGFBPs but native affinity for IGF-1R) demonstrated an enhanced effect of E 2 on growth factor stimulated terminal end bud formation and alveolar development in mammary gland [68] there has been a great deal of interest in the mechanistic aspects of this hormone-growth factor interaction.
As discussed above, the main route described for IGF cross talk to oestrogen signalling mechanisms is through the regulation of ER activity by IGF-1. In vitro this has usually been reported as an alteration in phosphorylation status of ER following IGF-1 treatment. Although ER is subject to extensive post translational modifications [69] the growth factor mediated phosphorylation of serine residues S118 and S167 in the AF-1 domain of human ER have been the most intensively studied and there is some evidence that this route of E 2 independent activation of ER may be partly involved in the development and maintenance of tumourigenesis in breast tissue [1, 70, 71] . In this fashion, IGF-1 (and other GFs) may allow the escape of ER + breast tumours from anti-oestrogen therapeutic regimens [72, 73] . It is important to note however that this hypothesis is challenged by clinical data which relate the phosphorylation status of ER with such parameters as disease free survival (DFS) in various cohorts (see below).
IGF-1 stimulates serine phosphorylation of ER at S118 in an Akt dependent manner [74] and the receptor is subsequently translocated to the cell membrane with resulting activation of the MAPK cascade [61, 75] . It is known that IGF-1 acts via MAPK to phosphorylate ER at S118 [76] and this suggest that both Akt and MAPK signalling pathways converge at S118. The significance of these findings is not fully understood but different pathways of IGF-1 signalling may show cell specificity in activation profiles. IGF-1 also acts via PI3K/Akt to phosphorylate at S167 within the AF-1 domain of ER [77] and phosphorylated ER subsequently associates with many components of the IGF signalling pathway including IRS proteins [78] , Shc [79] PI3K [80] and IGF-1R itself [81] . In this manner ER may regulate the expression, stability and intracellular localisation of these signalling intermediates [75, 82, 83] . Recent studies suggest that mTor/S6K1 lies down stream of Akt in the pathway of S167 phosphorylation although somewhat unusually this study did not demonstrate simultaneous S118 phosphorylation of ER after IGF-1 treatment of MCF-7 cells [84] . The ER protein is in fact a somewhat promiscuous substrate and is phosphorylated at S118 by several different kinases [85] [86] [87] . Whether there is a cell or tissue type specificity associated with individual kinase activity on ER remains largely unknown but further elucidation of specificities associated with kinase modification of ER activity is of obvious physiological significance.
There may also be important developmental and temporal aspects associated with
IGF-E axis interaction in breast tissue. An elegant study using transgenic mice expressing IGF-1 in the mammary gland from the bovine keratin 5 (BK5) promoter demonstrated developmentally regulated control of IGF-E crosstalk. In pre-pubertal animals IGF-1 signalling was dominated by the PI3K/Akt pathway and the presence of an IRS-1/ER complex was clearly identified. In post pubertal animals with lower levels of ER expression no such complex was observed and the main route for signalling proceeded via the Ras/Raf MAPK pathway [88] . Such differences in signalling patterns may differentially affect tumourigenesis during different developmental stages and indicate a potential role for ER in routing IGF signalling pathways. IGF-1 may phosphorylate ER at sites other than S118/S167. Studies with S305A mutant ER suggest S305 as important IGF-1/IRS-1/Akt mediated phosphorylation site [89] and this modification may regulate acetylation at the nearby K303 residue regulating sensitivity of ER to E 2 activation [89, 90] . Two excellent reviews on the characterisation and physiological significance of phosphorylated ER isoforms are available [91, 92] Western blot of non-transfected MCF-7 cell conditioned medium despite the fact that the expression and secretion of these proteins by ER+ BC cell lines has been widely reported in the literature [95] . Despite these caveats the area of IGFBP crosstalk with
ERs is very new and no doubt will provide much interesting data in the near future.
It is interesting to position studies of IGF-ER crosstalk within a clinical setting.
Phosphorylation of ER is generally viewed as an activating post translational modification (PTM) [96, 97] and is postulated as a route of escape of ER+ BC cells from SERM therapeutic strategies -see above. However, some evidence from immunohistochemical (IHC) screening of archived BC tissues using a well characterised anti-pS118-ER antibody suggests that phosphorylation of ER at S118 is associated with longer relapse free survival and longer time to progression in tamoxifen treated cohorts [98, 99] . While this does not necessarily negate a role for IGF-1 stimulated phosphorylation at S118 as an activating PTM, at the moment it is difficult to reconcile these observations although other factors such as precise expression [102] . Knockdown of IGF-1R in MCF-7 cells using siRNA increases ER expression and the subsequently altered ER : ER ratio may increase apoptosis via activation of tumour suppressor p53 [103] . The phosphorylation of the ER isoform has also been described [104] although whether such modification is regulated by IGF axis activity is currently unknown. However the mouse ER is phosphorylated at S106 and S124 via the MAPK pathway [105] and as the former residue is conserved as S118 in human ER it raises the possibility that ER may be subject to similar IGF-1 mediated PTMs as ER . In addition ER has at least 5 alternatively spliced variants (ER 1-5) which are expressed in a cell and tissue specific manner and which may display differential functions [106] . A novel route for growth factor modulation of ER function may be through the regulation of the differential expression of receptor isoforms. To date there is little information in this area although it is a subject of ongoing research in our laboratories.
The G protein coupled oestrogen receptor (GPER30) is the most recently described ER [107] . This cell membrane associated protein is believed to be partly responsible for the rapid non-genomic effects of E 2 -reviewed in [108] . Very little data is available on crosstalk between GPER and the IGF axis although a recent report indicates that IGF-1 up regulates GPER expression in MCF-7 cells in a PKC /ERK dependent fashion [109] . Interestingly this effect was dependent on ER activity suggesting a close relationship between these two ERs. In addition IGF-1R
associates with the G protein linked chemokine receptor CXCR4 in the MDA-MB-231 cells leading to an IGF-1 mediated dissociation of G 2 and G subunits from the complex with associated stimulation of chemotaxis [110] . Whether such a mechanism(s) exists for the GPER receptor is currently unknown.
ER crosstalk to IGF axis
As indicated above the evidence for IGF -1 and/or IGF-2 expression in BC cell lines and in primary tumour epithelial cells is not convincing however mammary stromal cells express IGF-1 and -2 and this population may provide a source of local growth factor [111] .With this in mind an intriguing hypothesis suggests that E 2 increases vascular permeability via a VEGF dependent mechanism and thus allows access of circulating growth factors (including IGFs) to cell surface receptors [112] . The extent to which this mechanism may operate in the mammary gland requires further investigation. Irrespective of whether such a mechanism operates there is compelling data that E 2 can increase the expression of IGF-1R on the surface of BC epithelial cells [113] [114] [115] [116] . Up regulation of IGF-1R expression may occur through interaction between liganded ER and the trans-acting zinc finger transcription factor Sp1 at the IGF-1R promoter [117] . More recent evidence indicates that in the PC3 E 2 also influences the expression and activity of other IGF signalling components.
Perhaps one of the most important of these is the insulin receptor substrate (IRS)
family of signalling molecules [117] . These adaptor proteins directly bind to activated IGF-1R in a phosphotyrosine (pY) dependent manner and following their own receptor catalysed tyrosine phosphorylation provide docking sites for other proteins involved in IGF-1 signalling including the p85 subunit of PI3K, Grb2 and Jak1. As such the role of IRS family proteins in BC is a subject of intense study -reviewed in [125] . In essence E 2 acts as a positive factor in IRS function. Thus, as for IGF-1R, E 2 can enhance IRS-1 expression via activation of transcription factor Sp1 [126] . In addition, ER is reported to bind and stabilise IRS-1 protein [78] leading to increased signalling through the IGF-1 pathway [127] . The sum effect of ER action on IRS-1 is to reinforce the stimulatory action on IGF-1R function and provide a mitogenic drive toward cell division. In this context, it is important to appreciate that the ultimate molecular effect of IGF-E 2 cross talk is to enhance the transition of cells through the cell cycle process and involves the regulation of G1-S phase cell cycle progression through the regulation of key regulators such as cyclinD1 or c-myc [73] . Limitations of space prevent a detailed discussion of this area but the E 2 -IGF control of cell cycle regulation is an important area of research with respect to BC progression and the interplay between the axis in the control of this process is an area of active study [101, 128] . shown to inhibit growth of BC cells [15] and IGFBP-5 treatment of BC tumour cells in a xenograft mouse model has been shown to restore tamoxifen sensitivity [146] .
Similarly, the mechanism of action of the SERD fulvestrant may be associated with increased expression of IGFBP-5 in BCs [115] . Hs578T BC cell line whereas IGFBP-4 and -5 inhibited ceramide induced apoptosis [147, 148] . In an extension of these studies the direct IGF-independent effects of IGFBP-3 and -5 on cell survival, attachment and apoptosis were found to be regulated by the presence of fibronectin in the ECM [12] . 
Concluding remarks
Although this review has focussed on crosstalk between the E and IGF axes we would highlight to the reader that E also interacts with other growth factor axes.
Understanding the biology behind steroid-growth factor crosstalk has recently been emphasised as a 'knowledge gap' in a gap analysis conducted by a panel of breast cancer experts http://breast-cancer-research.com/content/15/5/R92. In the context of the mammary gland and BC perhaps the most significant of these is the crosstalk that exists between the ER and members of the EGF family [150, 151] . As for IGF-1 molecular crosstalk between EGF receptors and ER is bi-directional and such mechanisms may be associated with promotion of tumour cell growth. This area has been expertly reviewed [152] . In conclusion the interaction of E and IGF axes in the mammary gland is important not only for normal tissue function but may also be involved in breast tumour aetiology and progression. A further understanding of the mechanisms involved in this crosstalk will mostly likely impact on the future treatment of BCs which develop resistance to anti-oestrogen therapy.
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